These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28247267)

  • 1. Options for Treating Pain in Cancer Patients with Dysphagia.
    Mercadante S
    Drugs; 2017 Apr; 77(6):629-635. PubMed ID: 28247267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatives to oral opioids for cancer pain.
    Mercadante S; Fulfaro F
    Oncology (Williston Park); 1999 Feb; 13(2):215-20, 225; discussion 226-9. PubMed ID: 10079471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
    Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
    Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An abuse-deterrent, microsphere-in-capsule formulation of extended-release oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia.
    McCarberg BH; Kopecky EA; O'Connor M; Marseilles A; Varanasi RK; Thompson C; Fleming AB
    Curr Med Res Opin; 2016 Dec; 32(12):1975-1982. PubMed ID: 27668546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough pain in cancer patients.
    Zeppetella G
    Clin Oncol (R Coll Radiol); 2011 Aug; 23(6):393-8. PubMed ID: 21227666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
    Hwang IC; Bruera E; Park SM
    Am J Hosp Palliat Care; 2014 Feb; 31(1):109-11. PubMed ID: 23345613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options.
    Argoff CE; Kopecky EA
    Curr Med Res Opin; 2014 Dec; 30(12):2543-59. PubMed ID: 25244248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.
    Kim DY; Song HS; Ahn JS; Ryoo BY; Shin DB; Yim CY; Kim SY
    Support Care Cancer; 2010 Feb; 19(2):297-301. PubMed ID: 20213238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
    Mercadante S
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
    Payne R
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
    Clemens KE; Klaschik E
    Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid and adjuvant analgesics: compared and contrasted.
    Khan MI; Walsh D; Brito-Dellan N
    Am J Hosp Palliat Care; 2011 Aug; 28(5):378-83. PubMed ID: 21622486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cancer pain with transdermal fentanyl.
    Gourlay GK
    Lancet Oncol; 2001 Mar; 2(3):165-72. PubMed ID: 11902567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment of cancer pain: alternative routes of opioid administration.
    Ripamonti C; Zecca E; De Conno F
    Tumori; 1998; 84(3):289-300. PubMed ID: 9678610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing breakthrough pain.
    Mercadante S
    Curr Pain Headache Rep; 2011 Aug; 15(4):244-9. PubMed ID: 21424673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
    Borgbjerg FM; Rosenberg J
    Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl nasal spray (Lazanda) for pain.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
    Tawfik MO; Bryuzgin V; Kourteva G;
    Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.